<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371952</url>
  </required_header>
  <id_info>
    <org_study_id>RC20_0191</org_study_id>
    <nct_id>NCT04371952</nct_id>
  </id_info>
  <brief_title>DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)</brief_title>
  <acronym>DYNAMIC</acronym>
  <official_title>Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria: Prospective, Multicenter, Randomized, Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare a treatment with doxycycline vs a placebo as soon as the
      patient is confirmed COVID-19 + and before the onset of oxygen dependence with the aim of
      reducing or even abolishing the cytokine explosion and thus the evolution towards a serious
      form of the disease which can lead to death.

      Three criteria support the rational use of tetrcycline in COVI-19 (1) The coronaviruses is
      known to bind to metalloproteases (MMPs) of the host, in particular to ensure viral survival.
      Tetracyclines are known to chelate zinc from MMPs. Their chelating activity may help inhibit
      COVID19 infection by limiting its ability to replicate in the host. (2) Tetracyclines may
      also be able to inhibit the replication of positive-polarity single-stranded RNA viruses,
      such as COVID19 (demonstrated on the dengue virus). (3) In addition, tetracyclines are
      modulators of innate immunity (anti-inflammatory activity), a property used in the treatment
      of inflammatory skin diseases for many years. These modulating effects are noted on several
      targets of innate immunity: They can decrease the expression of NFKB, the release of
      inflammatory cytokines such as TNF-α, IL-1β and IL-6, inhibit granulomas inflammatory and
      free radical release.

      Tetracyclines could therefore participate in limiting the cytokine release induced by
      COVID19. Their lipophilic nature and their strong pulmonary penetration could allow them to
      inhibit viral replication.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients with Clinical Respiratory Aggravation</measure>
    <time_frame>after at least 48 hours of treatment</time_frame>
    <description>Percentage of patients with clinical worsening (SaO2 ≤ 93%) after at least 48 hours of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients hospitalized</measure>
    <time_frame>after at least 48 hours of experimental treatment</time_frame>
    <description>Percentage of patients hospitalized after at least 48 hours of experimental treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients requiring ventilatory assistance</measure>
    <time_frame>Day 0 to Day 28</time_frame>
    <description>Percentage of patients requiring ventilatory assistance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive SARS-CoV-2 PCR Test</measure>
    <time_frame>Day -1 or day 0 AND Day 7</time_frame>
    <description>Number of positive SARS-CoV-2 PCR tests on D-1 / D0 and D7 (+/- 2 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of symptoms</measure>
    <time_frame>Day 0 to Day 28</time_frame>
    <description>Duration of symptoms (fever, painful symptoms: headache, sore throat, dyspnea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>From day 0 until to the end of hospitalization or date of death for any cause, whichever came first, assessed up to 3 months after Day0</time_frame>
    <description>Total duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization intensive care or reanimation</measure>
    <time_frame>From day 0 until to the end of hospitalization or date of death for any cause, whichever came first, assessed up to 3 months after Day0</time_frame>
    <description>Duration of hospitalization in intensive care or reanimation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilatory assistance</measure>
    <time_frame>to the end of mechanical ventilatory assistance if any, assessed up to 3 months after Day0</time_frame>
    <description>Duration of mechanical ventilatory assistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of deaths related to SARS-CoV-2</measure>
    <time_frame>Day 28, or end of hospitalization if any (assessed up to 3 months after Day0)</time_frame>
    <description>Percentage of deaths related to SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE / SAE in both arms</measure>
    <time_frame>Day 28, or end of hospitalization if any (assessed up to 3 months after Day0)</time_frame>
    <description>Number of AE / SAE in both arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Doxycycline 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline capsule containing 2 tablets doxycycline 100mg over-encapsulated. Doxycycline is given at 200 mg once a day and administered per os during 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Doxycycline Placebo capsule 200 mg, containing 1 capsule of a marketed placebo = RODAEL placebo ( lactose, 380 mg / capsule). Doxycycline placebo is given once a day and administered per os during 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>comparison of doxycycline 200 mg/day to placebo</description>
    <arm_group_label>Doxycycline 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo : lactose, 380 mg/gélule</description>
    <arm_group_label>Doxycycline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman &gt; 45 years old.

          -  Patient with a positive SARS-CoV-2 PCR

          -  Patient with ENT and / or respiratory symptoms, without hospitalization criteria (no
             dyspnea, respiratory rate &lt;22 / min, SaO2 ≥ 94% in ambient air), or digestive signs.

          -  Patient with at least one of the following risk factors for unfavorable outcome:

               -  70 years, BMI&gt; 30, cardiovascular history (stroke, coronary artery disease,
                  complicated hypertension, cardiac surgery, NYHA III or IV heart failure),
                  respiratory pathology likely to decompensate during viral infection respiratory
                  failure, unbalanced and / or complicated diabètes, respiratory pathology likely
                  to decompensate in the event of of viral infection, patients with renal
                  insufficiency chronic dialysis, .cancer patients under treatment.

        Exclusion Criteria:

          -  Lactose-intolerant patients

          -  Patient needing immediate hospitalization for any medical reason

          -  Patient having more than 5 days of clinical symptoms at the inclusion visit

          -  Patients with a history of allergy to tetracyclines

          -  Pregnant or lactating women

          -  Patients participating in another clinical trial

          -  Patients with photosensitive skin pathology

          -  Patients treated with anticoagulant

          -  Patients treated with oral retinoids: isotretinoin, alitretinoin, acitretin

          -  Patients treated with vitamin A Patients treated with systemic antibiotics for the
             duration of treatment

          -  Patients treated with barbiturates, carbamazepine or phenytoin

          -  Patients with treatment that may have an effect on COVID-19 infection: chloroquine,
             hydroxychloroquine, remdesivir, ganciclovir, acyclovir, ribavirin, lopinavir-ritonavir

          -  Patients under guardianship or trusteeship or in safeguard of justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brigitte DRENO</last_name>
    <phone>2 40 08 31 18</phone>
    <phone_ext>0033</phone_ext>
    <email>brigitte.dreno@atlanmed.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amir KHAMMARI</last_name>
    <phone>240 08 32 80</phone>
    <phone_ext>0033</phone_ext>
    <email>amir.khammaro@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Avicenne - APHP</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eve MAUBEC</last_name>
      <phone>1 48 95 70 90</phone>
      <phone_ext>0033</phone_ext>
      <email>eve.maubec@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrice BONNET</last_name>
      <phone>5 56 79 58 23</phone>
      <phone_ext>0033</phone_ext>
      <email>fabrice.bonnet@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne DOMPMARTIN-BLANCHERE</last_name>
      <phone>2 31 27 25 10</phone>
      <phone_ext>0033</phone_ext>
      <email>dompmartin-a@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lionel PIROTH</last_name>
      <phone>3 30 29 33 05</phone>
      <phone_ext>0033</phone_ext>
      <email>lionel.piroth@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Thérèse Leccia</last_name>
      <phone>476769320</phone>
      <phone_ext>0033</phone_ext>
      <email>mtleccia@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Brigitte DRENO, PUPH</last_name>
      <phone>2 40 08 31 18</phone>
      <phone_ext>0033</phone_ext>
      <email>brigitte.dreno@atlanmed.fr</email>
    </contact>
    <contact_backup>
      <last_name>Amir Khammari</last_name>
      <phone>2 40 08 32 80</phone>
      <phone_ext>0033</phone_ext>
      <email>amir.khammari@chu-nantes.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

